



Boustead Singapore Limited
(Co. Reg. No. 197501036K)

82 Ubi Avenue 4
#08-01 Edward Boustead Centre
Singapore 408832

BOUSTEAD SCRIP DIVIDEND SCHEME – ISSUE PRICE OF NEW SHARES

Singapore, 5 August 2019

The Board of Directors (the “Board”) of Boustead Singapore Limited (the “Company”) refers to the previous announcement made on 27 May 2019 in relation to the application of the Boustead Scrip Dividend Scheme (the “Scrip Dividend Scheme”) to the final tax-exempt (one-tier) dividend of two (2) Singapore cent per ordinary share (“Share”) of the Company for the financial year ending 31 March 2019 (the “Dividend”).

The Share Transfer Books and the Register of Members of the Company closed at 5.00 p.m. on 2 August 2019 (the “Books Closure Date”) for the purpose of determining Shareholders’ entitlements to the Dividend.

In accordance with the terms of the Scrip Dividend Scheme, the issue price of a new Share to eligible shareholders who elect to participate in the Scrip Dividend Scheme in respect of the Dividend (“New Share”) shall be an amount in Singapore dollars (S\$) determined by the Directors and shall not be set at more than 10% discount to, nor shall it exceed the average of the last dealt prices per Share on the Singapore Exchange Securities Trading Limited (the “SGX-ST”) for each of the market days during the period commencing on 1 August 2019, the day on which the Shares were first quoted ex-dividend on the SGX-ST after the announcement of the Dividend and ending on 2 August 2019, being the Books Closure Date (the “Price Determination Period”).

The Board wishes to inform that the issue price of each New Share to be issued in lieu of the cash amount of the Dividend is S\$0.725 (the “Issue Price”) for each New Share which represents a discount equivalent to 2.7% of the amount which is the arithmetic average of the last dealt prices per Share on the SGX-ST for each of the two (2) market days during the Price Determination Period.

The Board has determined that fractional entitlements to new Shares under the Scrip Dividend Scheme shall be rounded up to the nearest whole number or otherwise dealt with in such manner as they may deem fit in the interests of the Company and which is/are acceptable to the SGX-ST.

Eligible Shareholders may elect to participate in the Scrip Dividend Scheme in relation to all (or part thereof) of the Dividend only, or they may make a permanent election to participate in the Scrip Dividend Scheme in respect to all (and not part only) of his or her entitlements to future qualifying dividends. Eligible shareholders who do not elect to participate in the Scrip Dividend Scheme will receive all of their respective entitlements to the Dividend in cash. The Dividend will be paid on or about 19 September 2019.

Shareholders who wish to receive the Dividend in cash need not take any action.

The Company will despatch the Notices of Election to eligible shareholders on or around 19 August 2019.

By Order of the Board

Alvin Kok
Company Secretary

About Boustead Singapore Limited

Established in 1828, Boustead Singapore Limited (SGX:F9D) is a progressive global Infrastructure-Related Engineering Services, Geo-Spatial Technology and Healthcare Group listed on the SGX Mainboard. Focusing on the niche engineering and development of key infrastructure to support economic growth in global markets, our strong suite of engineering services comprises Energy-Related Engineering and Real Estate Solutions.

Under Geo-Spatial Technology, we provide professional services and exclusively distribute Esri geo-spatial technology – the world’s leading geographic information system and location analytics platform – to major markets across Australia and parts of South East Asia. Our location analytics platform and digital infrastructure solutions are essential to create smart nations, smart cities and smart communities by solving the world’s largest problems through effective and sustainable planning, deployment and management of key infrastructure and resources.

In Healthcare, we provide niche innovative assistive technologies and transformational medical solutions that improve the daily lives of chronic disease patients in Asia, with a focus on rehabilitative care, sleep care and sports science.

With a vast global network stretching across Asia, Australia, Europe, Africa and the Americas, we are ready to serve the world. To date, we have undertaken infrastructure-related projects in 87 countries and territories globally.

In 2008 and 2009, we were recognised in the prestigious Forbes Asia 200 Best Under A Billion as one of the Asia Pacific’s 200 best public-listed corporations under US\$1 billion in revenue. In 2015, we were also the winner of the Singapore Golden Jubilee Business Award, in recognition of the best 50 Singapore corporations who have achieved and contributed to Singapore’s progress and success over the past half-century since independence. In 2017, we were ranked by FinanceAsia as Singapore’s Best Small-Cap in the annual Asia’s Best Companies Poll. We are also listed on the MSCI World Micro Cap Index, FTSE Global Small Cap Index, FTSE Developed Small Cap Index and FTSE ST Small Cap Index.

Visit us at www.boustead.sg.

Contact Information

For media and investor enquiries related to Boustead Singapore Limited, please contact:

Mr Keith Chu
Senior Vice President
Corporate Marketing & Investor Relations

Main: +65 6747 0016
DID: +65 6709 8112
Fax: +65 6741 8689
E-mail: keith.chu@boustead.sg